Pfizer Sues To Block Generic Caduet Until 2016

Law360, New York (March 25, 2008, 12:00 AM EDT) -- In a move that could stop Ranbaxy Laboratories Ltd. from marketing a generic version of the hybrid blood pressure and cholesterol drug Caduet until 2016, Pfizer Inc. lodged a declaratory judgment suit on Monday claiming that Ranbaxy's proposed generic would infringe two patents related to atorvastatin.

Pfizer filed its complaint in the U.S. District Court for the District of Delaware, seeking a judgment that Ranbaxy's copycat Caduet would infringe two patents Pfizer says are valid through July 16, 2016. The suit seeks injunctive relief barring Ranbaxy...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.